Is Recro Pharma (REPH) a Worthy Investment?
Artko Capital, an asset management firm, published its fourth-quarter 2021 investor letter – a copy of which can be downloaded here.
Posts Tagged ‘NASDAQ:REPH’
Here’s Why Taking Profits in Recro Pharma (REPH) Resulted to a Great Outcome for Artko Capital
Artko Capital LP, an investment management firm, published its second-quarter 2021 investor letter – a copy of which can be downloaded here.
Is REPH A Good Stock To Buy Now?
While the market driven by short-term sentiment influenced by the accomodative interest rate environment in the US, virus news and stimulus talks, many smart money investors are...
If You Own Recro Pharma (REPH) Stock, Should You Sell It Now?
Artko Capital recently released its Q2 2020 Investor Letter, a copy of which you can download here.
Is Recro Pharma Inc (REPH) A Good Stock To Buy?
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file ...
Recro Pharma Inc (REPH): Are Hedge Funds Right About This Stock?
Hedge funds are not perfect. They have their bad picks just like everyone else.
Did Hedge Funds Drop The Ball On Recro Pharma Inc (REPH)?
Before we spend days researching a stock idea we like to take a look at how hedge funds and billionaire investors recently traded that stock.
Recro Pharma, Inc. (REPH): Here are Midwood Capital Management’s Thoughts On The Pharmaceutical Company
Midwood Capital Management explained recent Recro Pharma (NASDAQ:REPH) stock price fluctuations in its Q1 2019 Investor Letter.
Here is What Artko Capital Thinks About Recro Pharma, Inc. (REPH)
Artko Capital recently released its Q1 2019 Investor Letter, which you can track down here.
13D Filing: Broadfin Capital and Recro Pharma Inc. (REPH)
Please follow Broadfin Capital (if you aren't already doing so) to get real-time email alerts whenever we publish an article about Broadfin Capital or update its stock holdings...
13D Filing: Broadfin Capital and Recro Pharma Inc. (REPH)
Please follow Broadfin Capital (if you aren't already doing so) to get real-time email alerts whenever we publish an article about Broadfin Capital or update its stock holdings...
13D Filing: Broadfin Capital and Recro Pharma Inc. (REPH)
Please follow Broadfin Capital (if you aren't already doing so) to get real-time email alerts whenever we publish an article about Broadfin Capital or update its stock holdings...
13D Filing: Broadfin Capital and Recro Pharma Inc. (REPH)
Please follow Broadfin Capital (if you aren't already doing so) to get real-time email alerts whenever we publish an article about Broadfin Capital or update its stock holdings...
Recro Pharma Inc (REPH): Here’s What’s Next
Recro Pharma Inc (NASDAQ:REPH) is one of the week's runners in biotech so far. The company just put out data from a late stage trial and gained more than 20% on the news.
Recro Pharma Inc. (REPH): Largest Shareholder Broadfin Capital Buys Even More Shares
An amended 13D filing with the Securities and Exchange Commission showed that Kevin Kotler's Broadfin Capital has acquired more shares of Recro Pharma Inc.
A Look At Recro Pharma Inc (REPH) and Alkermes Plc (ALKS)’s Topline Triumph
Recro Pharma Inc (NASDAQ:REPH) is up more than 27% on Wednesday after announcing data from its lead acute pain trial.
Jason Karp Takes Long Position In This Stock, Up By 480% This Year
Jason Karp’s Tourbillon Capital Partners recently filed a 13G form with the SEC indicating that it now owns 7.0% of the common shares of Recro Pharma Inc.
Healthcare Expert Kevin Kotler Boosts His Stake In Recro Pharma Inc. (REPH)
Kevin Kotler’s Broadfin Capital has filed a 13D with the Securities and Exchange Commission regarding its stake in Recro Pharma Inc. (NASDAQ:REPH).
Servicesource International Inc (SREV), Recro Pharma Inc (REPH): Altai Capital And Broadfin Capital’s Latest Moves
According to a recent filing with the Securities and Exchange Commission, Altai Capital, run by Rishi Bajaj, Toby Symonds and Steve Tesoriere, has increased its holding of ...
Sabby Management Adds Bioline RX Ltd (BLRX) & Recro Pharma Inc (REPH) to Its Equity Portfolio
In a couple of new filings with the SEC, Hal Mintz's Sabby Management disclosed adding two companies to its equity portfolio: Bioline RX Ltd (NASDAQ:BLRX) and Recro Pharma Inc...
Broadfin Capital Initiates Stake in Newly Public Recro Pharma Inc (REPH)
Broadfin Capital, managed by Kevin Kotler, has disclosed in a new filing with the U.S.
